Gross Profit Trends Compared: United Therapeutics Corporation vs Arrowhead Pharmaceuticals, Inc.

Biotech Giants: A Decade of Gross Profit Trends

__timestampArrowhead Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 20141750001162636000
Thursday, January 1, 20153820001396725000
Friday, January 1, 20161583331526100000
Sunday, January 1, 2017314077091619600000
Monday, January 1, 2018161423211429100000
Tuesday, January 1, 20191687955771331200000
Wednesday, January 1, 2020879920661375200000
Friday, January 1, 20211382870001563000000
Saturday, January 1, 20222328100001789600000
Sunday, January 1, 20232407350002070000000
Monday, January 1, 20243551000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotechs: Gross Profit Trends Over a Decade

In the competitive world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, United Therapeutics Corporation and Arrowhead Pharmaceuticals, Inc. have shown contrasting trends in their gross profits. From 2014 to 2023, United Therapeutics consistently outperformed Arrowhead, with gross profits peaking at approximately $2.07 billion in 2023, marking a 78% increase from 2014. In contrast, Arrowhead's gross profits, while showing growth, remained significantly lower, peaking at around $240 million in 2023. This represents a staggering 137,000% increase from their modest start in 2014. The data highlights United Therapeutics' steady financial strength and Arrowhead's rapid growth trajectory, albeit from a smaller base. As we look to the future, these trends offer insights into the evolving landscape of the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025